{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:22:08Z","timestamp":1785525728567,"version":"3.56.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"the National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Candida glabrata is the second most common species responsible for invasive candidiasis, including candidaemia. Echinocandins are typically the first-line therapy for C. glabrata candidaemia, with the option to transition to oral fluconazole. Studies are needed to evaluate clinical outcomes in patients initially treated with echinocandins then transitioned to fluconazole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, single-centre cohort study of patients with C. glabrata candidaemia from November 2011 to August 2023. Inpatients aged 18\u201389\u2005years who received an echinocandin within 24\u2005h of the initial positive blood culture were included. Patients were excluded if they received antifungal treatment less than 48\u2005h, combination therapy, or fluconazole as initial therapy. The primary composite outcome was 30-day clinical failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 186 patients were included (n\u200a=\u200a153 echinocandin only; n\u200a=\u200a33 fluconazole step-down). The most common source of candidaemia was line-associated in both groups with the majority having source control (43% echinocandin versus 58% fluconazole; P\u200a=\u200a0.32). Compared to fluconazole, patients in the echinocandin group had a higher rate of concomitant bacteraemia (45% versus 24%; P\u200a=\u200a0.03) and endovascular complications (11% versus 0%; P\u200a=\u200a0.05). There was no significant difference in treatment duration between echinocandin and fluconazole (16 versus 19\u2005days; P\u200a=\u200a0.46), incidence of persistent candidaemia (22% versus 24%; P\u200a=\u200a0.7), or 30-day clinical failure (15% versus 9%; P\u200a=\u200a0.58).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fluconazole appears to be a safe and reasonable step-down therapy in the management of C. glabrata candidaemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf026","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:06:09Z","timestamp":1738051569000},"page":"996-1000","source":"Crossref","is-referenced-by-count":4,"title":["Fluconazole step-down therapy versus echinocandins for the treatment of <i>Candida glabrata<\/i> invasive candidiasis with candidaemia"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3915-946X","authenticated-orcid":false,"given":"Madeline","family":"Droney","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The University of Kansas Health System , Kansas City, KS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-7799","authenticated-orcid":false,"given":"Erica","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-3209","authenticated-orcid":false,"given":"Sajed","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University Wexner Medical Center , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-5512","authenticated-orcid":false,"given":"Kelci","family":"Coe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University Wexner Medical Center , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-7375","authenticated-orcid":false,"given":"Nikki","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2025040208373090000_dkaf026-B1","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2025040208373090000_dkaf026-B2","author":"Centers for Disease Control and Prevention 2024"},{"key":"2025040208373090000_dkaf026-B3","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025040208373090000_dkaf026-B4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025040208373090000_dkaf026-B5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"2025040208373090000_dkaf026-B6","author":"CLSI"},{"key":"2025040208373090000_dkaf026-B7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2025040208373090000_dkaf026-B8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/jac\/dks482","article-title":"Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study","volume":"68","author":"Eschenauer","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025040208373090000_dkaf026-B9","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1128\/AAC.00195-16","article-title":"Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections","volume":"60","author":"Puig-Asensio","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208373090000_dkaf026-B10","doi-asserted-by":"publisher","first-page":"e00631-17","DOI":"10.1128\/AAC.00631-17","article-title":"Initial treatment of cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia: better outcome with an echinocandin or polyene compared to an azole?","volume":"61","author":"Le","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208373090000_dkaf026-B11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2025040208373090000_dkaf026-B12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/myc.13290","article-title":"Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: a systematic review and network meta-analysis","volume":"64","author":"Demir","year":"2021","journal-title":"Mycoses"},{"key":"2025040208373090000_dkaf026-B13","doi-asserted-by":"publisher","first-page":"106614","DOI":"10.1016\/j.ijantimicag.2022.106614","article-title":"Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses","volume":"60","author":"Domingos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025040208373090000_dkaf026-B14","doi-asserted-by":"publisher","first-page":"ofab250","DOI":"10.1093\/ofid\/ofab250","article-title":"Early stepdown from echinocandin to fluconazole treatment in candidemia: a post hoc analysis of three cohort studies","volume":"8","author":"Moreno-Garc\u00eda","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025040208373090000_dkaf026-B15","doi-asserted-by":"publisher","first-page":"e19494","DOI":"10.1097\/MD.0000000000019494","article-title":"A multicenter retrospective analysis of the antifungal susceptibility patterns of Candida species and the predictive factors of mortality in South Korean patients with candidemia","volume":"99","author":"Jung","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025040208373090000_dkaf026-B16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2334-14-97","article-title":"Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial","volume":"14","author":"Vazquez","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025040208373090000_dkaf026-B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10096-019-03477-3","article-title":"Persistent candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era","volume":"38","author":"Agnelli","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"2025040208373090000_dkaf026-B18","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1128\/AAC.00296-07","article-title":"Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia","volume":"51","author":"Rodr\u00edguez-Tudela","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208373090000_dkaf026-B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1469-0691.2007.01899","article-title":"EUCAST technical note on fluconazole","volume":"14","year":"2008","journal-title":"CMI"},{"key":"2025040208373090000_dkaf026-B20","doi-asserted-by":"publisher","first-page":"ofaa270","DOI":"10.1093\/ofid\/ofaa270","article-title":"Impact of infectious disease consultation in patients with candidemia: a retrospective study, systematic literature review, and meta-analysis","volume":"7","author":"Kobayashi","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/996\/61658555\/dkaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/996\/61658555\/dkaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:07:58Z","timestamp":1743584878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/996\/7985147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf026","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,28]]}}}